NCM·Healthcare·$391M·#56 / 520 in Healthcare
XFOR X4 Pharmaceuticals, Inc.
70SOLID
CATEGORY BREAKDOWN
GROWTH100
QUALITY100
STABILITY83
VALUATION0
GOVERNANCE3
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+1273.2%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
83.6%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
30 months
93
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
41.5%
64
< 25% strong
Price / Sales
Market cap relative to trailing revenue
43.4x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
1026
100
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.5%
4
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+1084.9%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE XFOR WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when XFOR's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.